The Chronic Obstructive Pulmonary Disease Market growth is creating opportunities in emerging biologics and targeted therapies that address specific inflammatory endotypes. Eosinophilic COPD patients may benefit from anti-IL5 and anti-IL4/13 therapies originally developed for asthma. Anti-TNF approaches and other cytokine-targeted strategies are in clinical development. Additionally,...